Testicular cancer: treatment raises risk for 2nd primary malignancy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • No increased risk for second malignant neoplasm (SMN) in patients with testicular germ cell cancer (GCC) followed by surveillance. 
  • SMN risk and mortality increased after retroperitoneal radiotherapy (RT), bleomycin, etoposide, and cisplatin (BEP), or 1 line of treatment (MTOL).